Q-omics provides the consensus-scored SLC2A6 profile across patient tissues and cancer cell-line models. SLC2A6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC2A6 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, SLC2A6 RNA expression shows 16,783 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where SLC2A6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC2A6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC2A6 survival associations across molecular data types. SLC2A6 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC2A6 RNA expression–survival associations across cancer types. High SLC2A6 expression shows unfavorable associations in KIRC, UVM, ACC, MESO and LIHC, but favorable associations in UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC2A6 RNA expression.
This table summarizes SLC2A6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC2A6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC2A6 shows higher tumor expression in HNSC, STAD, COAD, BLCA, KIRC and UCEC. The HNSC box plot shows higher SLC2A6 RNA expression in tumor versus normal tissue (log2 FC = +2.068, t-test p < 0.001).
This table shows molecular features associated with SLC2A6 in patient tissues and cancer cell lines. In patient samples, SLC2A6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC2A6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
